Neuroblastoma (NB)Phase 3NB-NK-2026NCT07375563
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
A Phase 3 study testing Dinutuximab beta, temozolomide, irinotecan, autologous NK cell and irinotecan, temozolomide, dinutuximab beta, NK-cell product in people with Neuroblastoma (NB) and Ganglioneuroblastoma, run by Federal Research Institute of Pediatric Hematology, Oncology and Immunology at 1 site in Russia.
Trial summary
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the most common and life-threatening extracranial tumor in childhood. Read more about this study
- Who is it for?
- Ages 18 months to 18 years
- Conditions the study is for
- Neuroblastoma (NB), Ganglioneuroblastoma
- What is being tested?
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell and irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteRussia
- Study dates
- 19 Nov 2025to 19 Nov 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 months to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Signed voluntary informed consent to participate in the clinical trial
- Histologically verified diagnosis of neuroblastoma or ganglioneuroblastoma
- Patients stratified to the high-risk group according to the criteria of the German Society of Pediatric Oncology and Hematology (GPOH) - NB 2004, aged from 18 months to 18 years, and meeting the following conditions:
- Arm A: Refractory disease - patients who have completed the induction phase of therapy (6 cycles of N5/N6) with a poor response to therapy (MR, SD), with the exception of PD
- Arm В: Relapsed/progressive disease - patients who develop any new tumor lesions (after having previously achieved СR), or any new tumor lesion; an increase of >25% in any previously existing measurable lesion; or newly detected bone marrow involvement by NB cells in cases where the bone marrow had previously been free of involvement
- Performance status ≥ 70% (Lansky or Karnofsky scale) at the time of determining the indication for chemoimmunotherapy combined with NK cell therapy.
Show all 14Show fewer
- Expected life expectancy ≥ 12 weeks.
- No signs of drug-induced neuropathy or neuropathic pain.
- Adequate liver function: alanine aminotransferase (ALT) / aspartate aminotransferase (AST) activity < 5 × upper limit of normal (ULN).
- Adequate renal function: creatinine clearance or glomerular filtration rate (GFR) > 60 mL/min/1.73 m².
- Coagulation parameters: prothrombin index (PTI) 70-120%; activated partial thromboplastin time (APTT) < 36 seconds.
- No clinical signs of heart failure; left ventricular ejection fraction (LVEF) ≥ 55%.
- Adequate respiratory function (oxygen saturation by pulse oximetry > 94% on room air, no dyspnea at rest), and no pathological findings on chest X-ray.
- Completion of comprehensive assessment to evaluate the extent of the tumor process.
Who cannot join
- Lack of a signed voluntary informed consent form for participation in the clinical study.
- Absence of comprehensive pre-treatment assessment results at the time of initiation of specific therapy.
- Patients with NBL or ganglioneuroblastoma stratified to low or intermediate-risk group
- Good response (PR, VGPR, CR) or PD at the end of the induction phase of therapy (applicable only to patients receiving therapy within the framework of the intensified induction phase).
- Progressive or relapsed disease with central nervous system involvement and/or leptomeningeal involvement.
- History of acute intolerance reactions to the main chemotherapeutic and immunobiological agents and supportive care drugs used in this clinical trial protocol.
Show all 11Show fewer
- Presence of complications of the underlying disease and comorbidities that preclude treatment within this protocol, including severe type I hypersensitivity reactions in the medical history.
- Requirement for concomitant medications with known cross pharmacodynamic interactions with the drugs used in this clinical trial protocol.
- Presence of ultrasonographic signs of heart failure (LVEF ≤ 55%), clinical and laboratory signs of chronic kidney disease of stage ≥ III, or kidney injury of grade I, F or L according to the standardized RIFLE criteria for acute kidney injury (an acronym for "risk, injury, failure, loss, end-stage").
- Pregnancy, due to the high teratogenicity and toxicity of the drugs used in this clinical trial protocol. Female patients of childbearing potential are required to undergo pregnancy testing.
- Mental illness of the patient or legal guardians that makes it impossible to understand the nature of the study and compromises adherence to medical prescriptions and sanitary-hygienic requirements.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
Moscow, 117198
Lena Smirnova, +7 495 287 65 ext. 5551, lena.smirnova@dgoi.ru
About this study
Official title: Chemoimmunotherapy Combined With Autologous NK Cell Therapy for the Treatment of Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the most common and life-threatening extracranial tumor in childhood.
Patients with stage 4 high-risk NB is the subgroup with the poorest prognosis. Within this group, two subgroups with an extremely unfavorable disease course are distinguished: patients with a poor response to the induction phase of therapy (refractory disease) and patients with relapsed or progressive disease.
Read more
Nowadays, 10-15% of patients show a poor end-induction response, whereas achieving a good end-induction response associated with better long-term survival. Improvement of the response to induction therapy may contribute to better treatment outcomes in newly diagnosed high-risk NB patients and can be achieved by intensification of the induction phase to decrease the number of patients with refractory disease. Also intensification of the second-line therapy may contribute to better responses in patients with relapsed and progressive disease.
Protocol aimed to overcome heterogeneous tumor drug resistance through the synergistic interaction of cytostatic and immunobiological agents in combination with NK cell therapy.
This approach combines cytotoxic agents with anti-GD2 monoclonal antibodies (mAb) to enhance antitumor activity. Cultured, ex vivo-activated autologous NK cells are infused to compensate for effector cell depletion during therapy and to augment antibody-dependent cellular cytotoxicity (ADCC), potentially improving clinical outcomes.
This comprehensive approach opens novel prospects for enhancing treatment efficacy in patients with refractory and relapsed high-risk NB.
The expected outcomes of this protocol include a significant increase in therapeutic efficacy indicators - objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS), as well as in patient quality of life.
Read the detailed description
The study design evaluates a therapeutic interventionin two independent groups:
- Arm А: patients with a refractory disease
- Arm B: patients with relapsed/ progression disease
Intervention plan for patients with a refractory NB (arm A):
Patients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product), with an inter-cycle interval of 21 days. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course.
Intervention plan for patients with relapsed/progression (arm В):
Patients who meet the inclusion criteria will undergo peripheral blood collection with subsequent isolation of mononuclear cells for cultivation and expansion of an autologous NK cell product (Day -1), followed by administration of the first course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and five courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + autologous NK cell product) with a 21-day inter-cycle interval within the framework of this clinical trial protocol. Subsequent phases of therapy (including delayed surgery and external beam radiotherapy) will be carried out after completion of the chemoimmunotherapy in combination with autologous NK cell therapy, outside the present protocol, in accordance with current clinical practice. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course.
- Conditions
- Neuroblastoma (NB), Ganglioneuroblastoma
- Being tested
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Keywords
- Refractory/relapsed neuroblastoma, ganglioneuroblastoma, children, autologous NK cells, chemoimmunotherapy, dinutuximab beta
- Medical subject headings
- Neuroblastoma, Ganglioneuroblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dinutuximab beta, temozolomide, irinotecan, autologous NK cellCombination product
As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product), with an inter-cycle interval of 21 days. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course.
irinotecan, temozolomide, dinutuximab beta, NK-cell productCombination product
Patients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product)
| Study group | Role | What they receive |
|---|---|---|
| Arm А: patients with a refractory disease | Experimental | Patients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product) Receives: Combination Product: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell; Combination Product: irinotecan, temozolomide, dinutuximab beta, NK-cell product |
| Arm B: patients with relapsed/ progression disease | Experimental | Patients who meet the inclusion criteria will undergo peripheral blood collection with subsequent isolation of mononuclear cells for cultivation and expansion of an autologous NK cell product (Day -1), followed by administration of the first course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and five courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + autologous NK cell product) Receives: Combination Product: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell; Combination Product: irinotecan, temozolomide, dinutuximab beta, NK-cell product |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tolerability and toxicity of chemoimmunotherapy in combination with NK cell therapy.
(Proportion of patients receiving at least 80% of the planned doses without grade ≥ 3 adverse immunological reactions (ADRs) related to the NK cell product, assessed acc
Measured: immediately after completion of courses of chemoimmunotherapy in combination with NK cell therapy.
Secondary outcomes (4)
ORR after completion of chemoimmunotherapy courses in combination with NK cell therapy.
(The proportion of patients with a good response (CR, VGPR and PR) to therapy, assessed in accordance with the International Response Criteria for Patients with NB)
Measured: immediately after completion of courses of chemoimmunotherapy in combination with
ORR after completion of study therapy.
(The proportion of patients who achieved a good response (CR, VGPR and PR) to therapy, assessed in accordance with the International Response Criteria for Patients with NB)).
Measured: immediately after completion of study therapy.
OS and EFS at 1 year, 3 years, and 5 years after completion of study therapy.
For patients with refractory disease: The proportion of surviving patients, regardless of disease status (for OS) and the proportion of patients without adverse events, such as relapse, progression or death (for EFS)).
Measured: 1 year, 3 years, and 5 years from the date of diagnosis.
OS, PFS, and RFS at 1 and 3 years after completion of the study therapy.
For patients with progression/relapsed disease: The proportion of surviving patients from the time of diagnosis, regardless of disease status (for OS); the proportion of patients without disease relapse (for RFS) or disease progression (for PFS) from the time of the relapse or progression).
Measured: are 1, 3, and 5 years from the date of diagnosis (for OS) or from the date of documented progression/relapse (for PFS and RFS)).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2026
- Study start19 Nov 2025
- Primary completion15 Dec 2026 (estimated)
- Study completion19 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuroblastoma (NB)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 5 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Tatyana V Shamanskaya, MD, PHD, Study director, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07375563
- Sponsor's protocol ID
- NCHPOI- 2025-10
- Acronym
- NB-NK-2026
- Status last verified
- Jan 2026
- First submitted
- 15 Jan 2026
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for the Treatment of Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
- ClinicalTrials.gov ID
- NCT07375563
- Acronym / sponsor ID
- NB-NK-2026 / NCHPOI- 2025-10
- Conditions
- Neuroblastoma (NB), Ganglioneuroblastoma
- Keywords
- Refractory/relapsed neuroblastoma, ganglioneuroblastoma, children, autologous NK cells, chemoimmunotherapy, dinutuximab beta
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 5 participants (estimated)
- Lead sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyUniversity, hospital or other
- Study start
- 19 Nov 2025 (actual)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 19 Nov 2028 (estimated)
- First posted
- 29 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the most common and life-threatening extracranial tumor in childhood.
Patients with stage 4 high-risk NB is the subgroup with the poorest prognosis. Within this group, two subgroups with an extremely unfavorable disease course are distinguished: patients with a poor response to the induction phase of therapy (refractory disease) and patients with relapsed or progressive disease.
Nowadays, 10-15% of patients show a poor end-induction response, whereas achieving a good end-induction response associated with better long-term survival. Improvement of the response to induction therapy may contribute to better treatment outcomes in newly diagnosed high-risk NB patients and can be achieved by intensification of the induction phase to decrease the number of patients with refractory disease. Also intensification of the second-line therapy may contribute to better responses in patients with relapsed and progressive disease.
Protocol aimed to overcome heterogeneous tumor drug resistance through the synergistic interaction of cytostatic and immunobiological agents in combination with NK cell therapy.
This approach combines cytotoxic agents with anti-GD2 monoclonal antibodies (mAb) to enhance antitumor activity. Cultured, ex vivo-activated autologous NK cells are infused to compensate for effector cell depletion during therapy and to augment antibody-dependent cellular cytotoxicity (ADCC), potentially improving clinical outcomes.
This comprehensive approach opens novel prospects for enhancing treatment efficacy in patients with refractory and relapsed high-risk NB.
The expected outcomes of this protocol include a significant increase in therapeutic efficacy indicators - objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS), as well as in patient quality of life.
Detailed description
The study design evaluates a therapeutic interventionin two independent groups:
- Arm А: patients with a refractory disease
- Arm B: patients with relapsed/ progression disease
Intervention plan for patients with a refractory NB (arm A):
Patients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product), with an inter-cycle interval of 21 days. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course.
Intervention plan for patients with relapsed/progression (arm В):
Patients who meet the inclusion criteria will undergo peripheral blood collection with subsequent isolation of mononuclear cells for cultivation and expansion of an autologous NK cell product (Day -1), followed by administration of the first course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and five courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + autologous NK cell product) with a 21-day inter-cycle interval within the framework of this clinical trial protocol. Subsequent phases of therapy (including delayed surgery and external beam radiotherapy) will be carried out after completion of the chemoimmunotherapy in combination with autologous NK cell therapy, outside the present protocol, in accordance with current clinical practice. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm А: patients with a refractory disease | Experimental | Combination Product: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, Combination Product: irinotecan, temozolomide, dinutuximab beta, NK-cell productPatients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product) |
| Arm B: patients with relapsed/ progression disease | Experimental | Combination Product: Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, Combination Product: irinotecan, temozolomide, dinutuximab beta, NK-cell productPatients who meet the inclusion criteria will undergo peripheral blood collection with subsequent isolation of mononuclear cells for cultivation and expansion of an autologous NK cell product (Day -1), followed by administration of the first course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and five courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + autologous NK cell product) |
Who may qualify
- Ages
- 18 months to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (14 listed)
- Signed voluntary informed consent to participate in the clinical trial
- Histologically verified diagnosis of neuroblastoma or ganglioneuroblastoma
- Patients stratified to the high-risk group according to the criteria of the German Society of Pediatric Oncology and Hematology (GPOH) - NB 2004, aged from 18 months to 18 years, and meeting the following conditions:
- Performance status ≥ 70% (Lansky or Karnofsky scale) at the time of determining the indication for chemoimmunotherapy combined with NK cell therapy.
- Expected life expectancy ≥ 12 weeks.
Key exclusion criteria (11 listed)
- Lack of a signed voluntary informed consent form for participation in the clinical study.
- Absence of comprehensive pre-treatment assessment results at the time of initiation of specific therapy.
- Patients with NBL or ganglioneuroblastoma stratified to low or intermediate-risk group
- Good response (PR, VGPR, CR) or PD at the end of the induction phase of therapy (applicable only to patients receiving therapy within the framework of the intensified induction phase).
- Progressive or relapsed disease with central nervous system involvement and/or leptomeningeal involvement.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dinutuximab beta, temozolomide, irinotecan, autologous NK cellAs part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product), with an inter-cycle interval of 21 days. Transfusion of the autologous NK cell product will be performed on Day 7 of each DIT course. | Combination product | Arm B: patients with relapsed/ progression disease, Arm А: patients with a refractory disease |
| irinotecan, temozolomide, dinutuximab beta, NK-cell productPatients who meet the inclusion criteria will undergo an intensified induction phase within the framework of this clinical trial protocol, while the preceding induction phase and subsequent consolidation and post-consolidation phases will be performed outside of this protocol in accordance with the current clinical practice. As part of the intensified induction, a procedure for the collection of mononuclear cells for the cultivation and expansion of the autologous NK cell product (Day -1) is planned, followed by one course of chemotherapy according to the IT regimen (irinotecan + temozolomide) and four courses of chemoimmunotherapy in combination with autologous NK cell therapy according to the DIT regimen (irinotecan + temozolomide + dinutuximab beta + NK-cell product) | Combination product | Arm B: patients with relapsed/ progression disease, Arm А: patients with a refractory disease |
Primary outcome
Tolerability and toxicity of chemoimmunotherapy in combination with NK cell therapy.
Time frame: immediately after completion of courses of chemoimmunotherapy in combination with NK cell therapy.
(Proportion of patients receiving at least 80% of the planned doses without grade ≥ 3 adverse immunological reactions (ADRs) related to the NK cell product, assessed acc
4 secondary outcomes
ORR after completion of chemoimmunotherapy courses in combination with NK cell therapy.
Time frame: immediately after completion of courses of chemoimmunotherapy in combination with
ORR after completion of study therapy.
Time frame: immediately after completion of study therapy.
OS and EFS at 1 year, 3 years, and 5 years after completion of study therapy.
Time frame: 1 year, 3 years, and 5 years from the date of diagnosis.
OS, PFS, and RFS at 1 and 3 years after completion of the study therapy.
Time frame: are 1, 3, and 5 years from the date of diagnosis (for OS) or from the date of documented progression/relapse (for PFS and RFS)).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Neuroblastoma (NB)
RecruitingPhase 2
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Neuroblastoma (NB), Neuroblastoma in Children
RecruitingEarly Phase 1
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Neuroblastoma (NB)
Active, not recruitingEarly Phase 1
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Neuroblastoma (NB)
RecruitingObservational study
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
Neuroblastoma (NB)
Enrolling by invitationObservational study
Risk Model for Metastasis Detection of Neuroblastoma
Neuroblastoma (NB), Prognosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tatyana V Shamanskaya, MD, PHD study director
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dinutuximab beta, temozolomide, irinotecan, autologous NK cell and irinotecan, temozolomide, dinutuximab beta, NK-cell product in people with Neuroblastoma (NB) and Ganglioneuroblastoma, run by Federal Research Institute of Pediatric Hematology, Oncology and Immunology at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tatyana V Shamanskay, MD, PHD (8 903 166-69-91, shamanskayatatyana@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tolerability and toxicity of chemoimmunotherapy in combination with NK cell therapy. (time frame: immediately after completion of courses of chemoimmunotherapy in combination with NK cell therapy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026; AzTrials last refreshed its copy on 26 Oct 2026.